Aethlon Medical has filed a prospectus for a mixed shelf offering, a move that provides the company with the flexibility to raise capital through various types of securities. The filing was submitted to the U.S. Securities and Exchange Commission (SEC), allowing the firm to register securities that may be offered and sold in the future.

The mixed shelf offering permits Aethlon Medical to issue different classes of securities, which could include common stock, preferred stock, debt securities, and warrants. By utilizing this registration method, the company can respond to market conditions and access capital markets more efficiently when needed, without having to file a new registration statement for each offering.

This financial strategy is often employed by companies seeking to streamline their capital-raising processes. The prospectus outlines the general terms under which the securities may be offered, though specific details regarding the amount and timing of any future sales will be determined by the company at the time of each offering.

Key Details of the Filing

The registration statement on Form S-1 becomes effective upon the SEC's declaration. Until then, the securities cannot be sold. This filing does not guarantee that the company will proceed with any specific offering, but it establishes the legal framework to do so.

Aethlon Medical, Inc. has announced the publication of peer-reviewed research in the International Journal of Molecular Sciences that identifies a novel biomarker for Long COVID and validates the potential of its Hemopurifier as a therapeutic target. The study, conducted in collaboration with the University of California, San Francisco (UCSF), reveals that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) compared to those who fully recovered from COVID-19 infection. These EVs can be captured using the Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Hemopurifier.

The research analyzed plasma samples from participants enrolled in UCSF's Long-term Impact of Infection with Novel Coronavirus (LIINC) study. It provides new evidence supporting extracellular vesicles as a potential therapeutic target in Long COVID. The findings help establish a translational framework for future studies to determine if the Hemopurifier can remove disease-associated EVs and their molecular cargo.

"The publication of this study contributes to the scientific understanding of the biological mechanisms underlying Long COVID while strengthening the rationale for evaluating the Hemopurifier in this significant area of unmet medical need," said Jim Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical.

Key Findings

The study's principal findings demonstrate the Hemopurifier's mechanism of action and its potential impact on Long COVID pathology:

Strategic Focus

While the company's current resources and primary focus remain dedicated to advancing its Australian oncology clinical trial, these findings provide additional translational evidence supporting future preclinical and clinical studies for Long COVID. Frakes emphasized that the findings reinforce the potential of the Hemopurifier as a platform technology with applications across multiple disease areas, describing it as a "pipeline within a single device."

The Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. It utilizes proprietary lectin-based technology to remove harmful EVs from biological fluids. The device holds a U.S. Food and Drug Administration (FDA) Breakthrough Device designation for the treatment of advanced or metastatic cancer and an open Investigational Device Exemption (IDE) application for life-threatening viruses.